Dr. Whelan on the Women the MA.20 Trial Benefits

Timothy J. Whelan, BM, BCh
Published: Monday, Jul 11, 2011



Lead study investigator Timothy J. Whelan, BM, BCh, professor of Oncology and the division head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, discusses the amount of women, by percent, that might benefit from the results of the NCIC-CTG MA.20 intergroup phase III trial for women with breast conserving surgery that usually receive whole breast irradiation.

Dr. Whelan says on average at least 50%, or perhaps even higher, have breast conserving surgery. Not all of those will be node positive.


Lead study investigator Timothy J. Whelan, BM, BCh, professor of Oncology and the division head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, discusses the amount of women, by percent, that might benefit from the results of the NCIC-CTG MA.20 intergroup phase III trial for women with breast conserving surgery that usually receive whole breast irradiation.

Dr. Whelan says on average at least 50%, or perhaps even higher, have breast conserving surgery. Not all of those will be node positive.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x